Intercept Pharmaceuticals Files For $75 Million U.S. IPO

Intercept Pharmaceuticals Files For $75 Million U.S. IPO

NEW YORK, Sept. 4, 2012 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Intercept. The number of shares to be offered and the price range for the offering have not yet been determined.

BofA Merrill Lynch is acting as sole book-running manager for the offering. BMO Capital Markets is acting as lead manager and Needham & Company, LLC, Wedbush PacGrow Life Sciences and ThinkEquity LLC are acting as co-managers.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold and offers to buy may not be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, and there shall not be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

Click Here For More Information:
http://community.nasdaq.com/News/2012-09/intercept-pharmaceuticals-files-for-a-75-million-us-ipo.aspx?storyid=169943


Do you currently have any idle surplus laboratory equipment that growing old on your dollar?  Give SSLLC.com a call, we can assist you with recovering income for your unwanted instruments.